1. France Stocks

  2. •

    Health services

  3. •

    Medical/Nursing services
Median Technologies

Median Technologies

4.11
EUR
-0.11
(-2.72%)
69.53MMarket Cap
Oct 29Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.12
0.19
0.39
0.55
0.64
0.53
0.74
1.11
1.33
1.5
1.21
1.24
0.64
- -
Basic EPS, GAAP
-0.37
-0.54
-0.55
-0.78
-1.44
-1.27
-0.66
-1.06
-1.25
-1.28
-1.25
-1.36
-0.93
- -
Free Cash Flow per Basic Share
-0.73
-0.42
-0.41
-0.69
-1.19
-1.32
-0.38
-0.48
-0.69
-1.09
-1.17
-1.03
-0.49
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
0.15
1.46
2.63
3.33
2.08
0.75
0.11
-0.94
0.32
-0.46
-0.56
-1.84
-0.96
-1.84
Tangible Book Value per Share
0.15
1.46
2.61
3.31
2.06
0.75
0.1
-0.95
0.31
-0.52
-0.66
-1.95
-1.01
-1.95
Basic Weighted Avg Shares
6
8
10
12
12
12
12
12
15
16
18
18
37
18
Sales/Revenue/Turnover
1
2
4
6
8
6
9
13
21
24
22
23
23
- -
Operating Margin (%)
-304.39
-290.27
-145.3
-144.74
-221.25
-241.51
-88.16
-64.72
-55.67
-97.91
-102.98
-97.46
-68.23
- -
Depreciation Expense
- -
- -
- -
- -
- -
1
1
1
1
1
1
2
3
- -
Net Income, GAAP
-2
-4
-6
-9
-17
-15
-8
-13
-19
-20
-23
-25
-34
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-304.39
-290.72
-142.27
-143.39
-223.86
-241.07
-89.2
-94.98
-93.89
-85.4
-103.4
-109.99
-145.85
- -
Working Capital
2
14
28
40
25
9
1
3
20
8
9
-24
-15
-24
LT Debt
1
1
- -
- -
- -
- -
1
16
16
18
19
9
19
9
Total Equity
1
12
26
39
25
9
1
-11
5
-7
-10
-34
-35
-34
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
-69.24
-28.88
-28.04
-54.04
-89.83
-153.92
- -
- -
- -
- -
- -
- -
- -

Capital Structure

EUR

•

in mil. unless spec.
Dec'23
Jun'24
Dec'24
ST Debt
1
20
20
LT Borrowings
19
8
9
LT Finance Leases
1
1
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
18
18
18
Market Capitalization
87
49
70

Working Capital

EUR

•

in mil. unless spec.
Dec'23
Jun'24
Dec'24
Total Current Assets
32
29
21
Cash, Cash Equivalents & STI
20
16
8
Accounts Receivable, Net
7
7
7
Inventories
- -
- -
- -
Total Current Liabilities
23
42
44
Payables & Accruals
- -
- -
- -
ST Debt
1
20
20
Deferred Revenue
- -
- -
- -

Growth Rates

EUR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-123.94%
-22.99%
3.49%
Free Cash Flow
29.57%
30.7%
-4.5%
Net Income, GAAP
26.91%
22.8%
34.98%
Sales/Revenue/Turnover
22.53%
13.32%
1.79%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
22
2024
- -
- -
23
2025
- -
- -
23

Semi-annual Earnings Per Share

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
-1.25
2024
- -
- -
-1.36
2025
- -
- -
-0.93

Semi-annual Dividends Per Share

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
- -
2024
- -
- -
- -
2025
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Fredrik Bjjorn Brag
Full Time Employees
199
Sector
Health services
Industry
Medical/Nursing services
Address
1800, Route des CrEtes Valbonne PAC France 06560
IPO Date
May 20, 2011
Website
mediantechnologies.com
Similar Companies
Hims & Hers Health, Inc. (NYSE:HIMS)
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA)
Mobile-health Network Solutions (NASDAQ:MNDR)
Dr. Lal PathLabs Limited (NSE:LALPATHLAB)
Tenon Medical, Inc. (NASDAQ:TNON)
Teladoc Health, Inc. (NYSE:TDOC)
Business
Median Technologies S.A. Median Technologies S.A. develops artificial intelligence-powered imaging solutions and services for oncology clinical trials and precision diagnostics. The company offers iCRO, an end-to-end imaging CRO platform for medical image analysis and management that supports biopharmaceutical companies in phase I through phase III oncology studies with AI-driven insights on patient responses, biomarker discovery, patient selection, disease monitoring, and regulatory submissions; and eyonis, a suite of AI/ML-based software as medical devices (SaMDs) including eyonis LCS for lung cancer screening detection and characterization, eyonis IPN for incidental lung cancer detection, and eyonis HCC for early liver cancer diagnosis, enabling clinicians to improve early detection, diagnostic accuracy, and patient monitoring. Median operates globally with teams in Europe (headquartered in Valbonne, France), the United States (Boston, MA), and China (Shanghai), serving over 80 biopharma clients, more than 2,500 clinical sites across 28 countries, and leveraging a workforce of over 230 professionals from 26 nationalities with expertise in clinical oncology imaging. Founded in 2002, the company recently completed a €23.9 million capital increase in August 2025 to support U.S. commercialization of eyonis LCS following FDA 510(k) application submission, secured a €37.5 million financing line with the European Investment Bank in July 2025, signed a €10 million bond financing agreement with Iris in January 2025, and intensified partnerships with leading U.S. AI diagnostic organizations and global CROs for eyonis suite expansion and iCRO repositioning, extending its cash runway through at least Q4 2026.